Ligand id: 7672

Name: brexpiprazole

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: brexpiprazole

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 73.05
Molecular weight 433.18
XLogP 4.42
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
In July 2015, brexpiprazole was approved by the US FDA for use in the treatment of schizophrenia in adults, and as an add-on treatment to an antidepressant medication in adults with major depressive disorder [1]. Brexpiprazole is also being investigated as a treatment for attention deficit hyperactivity disorder (ADHD). Click here to view's listing of current brexpiprazole drug trials.
Mechanism Of Action and Pharmacodynamic Effects
Brexpiprazole is a partial agonist of the dopamine D2 receptor [2].